Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Bispecific Anti-VEGF/Angiopoietin-2 antibodies

4 evidence topics · 4 sources

Faricimab: TENAYA and LUCERNE primary results

“Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A.” (opens the source at this quote in a new tab)

“Treatment-naive patients with nAMD aged 50 years or older were randomly assigned (1:1) to intravitreal faricimab 6·0 mg up to every 16 weeks, based on protocol-defined disease activity assessments at weeks 20 and 24, or aflibercept 2·0 mg every 8 weeks.” (opens the source at this quote in a new tab)

“BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]).” (opens the source at this quote in a new tab)

Faricimab: two-year results with treat-and-extend dosing

“At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing.” (opens the source at this quote in a new tab)

“Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals.” (opens the source at this quote in a new tab)

Faricimab: injection counts and inflammation in the AAO Preferred Practice Pattern

“Through year 2, the median number of injections in the faricimab group was 10, compared with 15 for aflibercept.” (opens the source at this quote in a new tab)

“Recently, case reports of intraocular inflammation (excluding endophthalmitis) with faricimab were as high as 2% and retinal vasculitis with or without occlusion were 0.17 per 10,000 injections (vasculitis) and 0.06 per 10,000 for occlusive vasculitis.” (opens the source at this quote in a new tab)

Faricimab: FDA-labeled dosing and retinal vasculitis warning

“Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses.” (opens the source at this quote in a new tab)

“Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of VABYSMO” (opens the source at this quote in a new tab)